BIOMAT Database Logo BIOMAT Database Logo

Restoration of normal gonadotropin responses to naloxone by chronic bromocriptine treatment in elderly men. 1991

V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Istituto di Clinica Medica Generale e Terapia Medica, Università di Parma, Italia.

Naloxone is unable to stimulate FSH and LH secretion in elderly men, suggesting a reduced endogenous opioid control of gonadotropin secretion in senescence. In the present study, we examined whether in elderly men a chronic dopaminergic stimulation with bromocriptine (5 mg/day for 7 days) modifies the gonadotropin response to naloxone (4 mg as an i.v. bolus plus 10 mg infused in 2 h). Eleven younger men (group 1, 22-40 years old) participated as controls. Twenty-two elderly men were selected from a larger population and were divided into two groups: subjects with compensated gonadal failure (normal blood testosterone and elevated gonadotropin concentrations; group 2, n = 11; 62-80 years old) and men with normal gonadal function (normal blood testosterone and gonadotropin levels; group 3, n = 11; 61-82 years old). Naloxone induced a striking LH and a slight but significant FSH increase in group 1, but was unable to change serum gonadotropin concentrations in elderly subjects of both groups 2 and 3. When experiments were repeated after bromocriptine treatment, no significant differences in LH and FSH responses to naloxone were observed in the younger subjects. On the other hand, bromocriptine restored significant gonadotropin responses to naloxone in elderly men. In fact, after bromocriptine, naloxone-induced FSH and LH increments in groups 2 and 3 were indistinguishable from those observed in group 1. These data suggest that in men age-related dopaminergic alterations may underlie the defective endogenous opioid control of gonadotropin secretion.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Effects of chronic bromocriptine-induced hypoprolactinemia on plasma testosterone responses to human chorionic gonadotropin stimulation in normal men.
February 1991, Fertility and sterility,
V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Bromocriptine effects on plasma luteinizing hormone and its responses to gonadotropin-releasing hormone in normal men.
January 1993, Life sciences,
V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Hormonal responses to a potent gonadotropin hormone-releasing hormone antagonist in normal elderly men.
October 1990, The Journal of clinical endocrinology and metabolism,
V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Plasma ACTH, cortisol, LH, FSH, testosterone, and dihydrotestosterone responses to bromocriptine in normal men.
February 1980, Archives of andrology,
V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Serum LH and FSH responses to synthetic gonadotropin-releasing hormone in normal men.
November 1975, The Journal of clinical endocrinology and metabolism,
V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Pulsatile gonadotropin-releasing hormone in gonadotropin deficient and normal men: suppression of follicle-stimulating hormone responses by testosterone.
July 1981, The Journal of clinical endocrinology and metabolism,
V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Chronic bromocriptine administration restores luteinizing hormone response to naloxone in postmenopausal women.
February 1988, Neuroendocrinology,
V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Adrenocorticotropin responses to naloxone in sons of alcohol-dependent men.
January 1999, The Journal of clinical endocrinology and metabolism,
V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Effects of bromocriptine on plasma catecholamines in normal men.
January 1979, Neuroendocrinology,
V Coiro, and R Volpi, and P Bertoni, and A Marcato, and S Vourna, and R Bocchi, and L Bianconi, and M Marchesi, and G Buonanno, and P Chiodera
Gonadotropin responses to naloxone may depend upon spontaneous activity in noradrenergic neurons at the time of treatment.
January 1986, Brain research,
Copied contents to your clipboard!